Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Zimmer said today that it’s proposing to sell of some of its knee and elbow assets in Europe to satisfy anti-trust regulators on the European Commission about its pending, $13.35 billion acquisition of cross-town orthopedics rival Biomet.
“Zimmer has been working closely with the EC to develop a mutually-acceptable solution to address the discrete concerns identified by the EC in its preliminary assessment of the proposed acquisition of Biomet,” the company said. Read more
2. China, South Korea OK Medtronic’s $43B Covidien buy
Chinese regulatory authorities have signed off on the planned $43 billion merger between Medtronic and Covidien, a major milestone as both companies push to conclude the transaction by end of the 2015 1st quarter.
The Chinese Ministry of Commerce’s clearance of the massive deal comes in tandem with the South Korean Fair Trade Commission’s acceptance of the M&A agreement, Medtronic said today. As well, the companies now have all necessary antitrust clearances in hand. Read more
Danaher said today that its Leica Biosystems division closed its buyout of Devicor Medical Products, a developer of breast biopsy products.
Leica Biosystems specializes in automated cancer diagnostics. Financial terms were not disclosed. Read more